Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Melanoma Inhibitory Activity (MIA): A Serological Marker for Metastatic Uveal Melanoma

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2006 by Ludwig-Maximilians - University of Munich.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Ludwig-Maximilians - University of Munich
ClinicalTrials.gov Identifier:
NCT00406900
First received: November 29, 2006
Last updated: December 5, 2006
Last verified: November 2006

November 29, 2006
December 5, 2006
January 1999
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00406900 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Melanoma Inhibitory Activity (MIA): A Serological Marker for Metastatic Uveal Melanoma
Not Provided

Uveal Melanoma is the most common primary intraocular tumor in adults. Most tumors metastasize to the liver. So far no sensitive or specific serological tumor marker is routinely used. The marker "Melanoma inhibitory activity" is a promising marker. Study hypothesis is to detect metastatic lesions in an early stage. This would increase life expectance of our patients

Serum is taken from each melanoma patient at every follow up after signed concent. With ELISA the marker MIA is evaluated. An increase of MIA serum level will lead to search for metastasis by oncologists.

Observational
Observational Model: Defined Population
Primary Purpose: Screening
Time Perspective: Longitudinal
Not Provided
Not Provided
Not Provided
Not Provided
  • Melanoma
  • Radiotherapy
  • Metastatic Disease
Procedure: Treatment of metastatic disease
Not Provided
Schaller UC, Bosserhoff AK, Neubauer AS, Buettner R, Kampik A, Mueller AJ. Melanoma inhibitory activity: a novel serum marker for uveal melanoma. Melanoma Res. 2002 Dec;12(6):593-9.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
560
September 2006
Not Provided

Inclusion Criteria:

  • uveal melanoma (With/without overt metastatic disease)
Both
Not Provided
No
Contact: Ulrich C Schaller, MD +49/89/5160 ext 3811 ulrich.schaller@med.uni-muenchen.de
Germany
 
NCT00406900
MIA
Not Provided
Not Provided
Ludwig-Maximilians - University of Munich
Not Provided
Principal Investigator: Ulrich C Schaller, MD University of Munich, Germany
Ludwig-Maximilians - University of Munich
November 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP